Works matching IS 17562856 AND DT 2011 AND VI 4 AND IP 5
Results: 5
Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2011, v. 4, n. 5, p. 319, doi. 10.1177/1756285611422108
- By:
- Publication type:
- Article
Intracranial aneurysms: optimized diagnostic tools call for thorough interdisciplinary treatment strategies.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2011, v. 4, n. 5, p. 267, doi. 10.1177/1756285611415309
- By:
- Publication type:
- Article
The interferon beta therapies for treatment of relapsing–remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta ...
- Published in:
- Therapeutic Advances in Neurological Disorders, 2011, v. 4, n. 5, p. 281, doi. 10.1177/1756285611413825
- By:
- Publication type:
- Article
Response of patients with refractory myasthenia gravis to rituximab: a retrospective study.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2011, v. 4, n. 5, p. 259, doi. 10.1177/1756285611411503
- By:
- Publication type:
- Article
Therapeutic potential of melatonin and its analogs in Parkinson’s disease: focus on sleep and neuroprotection.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2011, v. 4, n. 5, p. 297, doi. 10.1177/1756285611406166
- By:
- Publication type:
- Article